Company Profile
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company provides the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications.
Its portfolio also includes HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout, HP558, a product in phase II clinical trials to treat various late-stage cancers, and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer. Founded in 2013, Hinova Pharmaceuticals is headquartered in Chengdu, China.